Hyphens Pharma International Ltd. · SGX:1J5

Hyphens Pharma International — Q1 2020 Earnings Presentation

13 slides from Hyphens Pharma International's earnings presentation, May 14, 2020

  1. Slide 1: General Announcement: Results Briefing 1Q2020

    5/14/2020 General Announcement::RESULTS BRIEFING 1Q2020 GENERAL ANNOUNCEMENT::RESULTS BRIEFING 1Q2020 Issuer & Securities Issuer/ Manager HYPHENS PHARMA INTERNATIONAL LIMITED Securities HYPHENS PHARMA INTL LIMITED - SG1EE4000006 - 1J5 Stapled Security No Announcement Details Announcement Title Gener

  2. Slide 2: Attachment: Hyphens Results Briefing 1Q2020

    5/14/2020 General Announcement::RESULTS BRIEFING 1Q2020 Hyphens%20Results%20Brie ng%20-%201Q2020.pdf Total size =2348K MB https://links.sgx.com/1.0.0/corporate-announcements/12RH943NHTEFUYF4/305f5636e009eec1a773f9e3acad54b8d54c4d0a12d549052ce541d… 2/2

  3. Slide 3: Results Briefing 1Q2020 Disclaimer

    5/14/2020 Hyphens Pharma International Limited Results Briefing 1Q2020 HYPHENS PHARMA INTL LTD (SGX: 1J5) DISCLAIMER This presentation has been prepared by Hyphens Pharma International Limited (the "Company" and, together with its subsidiaries, the "Group"). This content in this presentation is bein

  4. Slide 4: Business Highlights: Our Strategic Focus

    5/14/2020 BUSINESS HIGHLIGHTS OUR STRATEGIC FOCUS ASEAN’s Leading Pharmaceuticals & Consumer Healthcare Group Long-term goal: Asia’s No. 1 Skin Health Company 2

  5. Slide 5: Impact from COVID-19

    5/14/2020 IMPACT FROM COVID-19 • Impact on operations - Continued to operate as part of essential services - Increase in supply lead time and freight costs • Impact on financial position - Strong cash position and operating cash inflow - Good position to seize opportunities • Pledging support - Comm

  6. Slide 6: Going Digital

    5/14/2020 GOING DIGITAL Well liked by consumers GOING DIGITAL Engaging medical professionals 4

  7. Slide 7: Going Digital: New Ceradan Website and Virtual Hypermart

    5/14/2020 GOING DIGITAL Introducing brand new Ceradan website www.ceradan.com GOING DIGITAL Revamped Virtual Hypermart www.pom.com.sg 5

  8. Slide 8: Investing for Growth

    5/14/2020 INVESTING FOR GROWTH 1• Establishing a broader geographical footprint - Cementing leadership position in Singapore and deepening presence in ASEAN - Expanding international footprint in Asia, Middle East and Africa 2• Investment in proprietary brands - Driving growth of skin health portfol

  9. Slide 9: Financial Highlights: Revenue & Profits Growth

    5/14/2020 FINANCIAL HIGHLIGHTS 1 REVENUE & PROFITS GROWTH (RECAP) Revenue (S$’m) Profit After Tax (S$’m) 6.5 6.1 112.7 120.9 119.4 101 5.4 78.3 5.2 5.1 FY2015 FY2016 FY2017 FY2018 FY2019 FY2015 FY2016 FY2017 FY2018* FY2019 * Incl IPO exp S$0.9m 7

  10. Slide 10: Strong Quarterly Revenue, Highest Quarterly Profits

    5/14/2020 1.1 STRONG QUARTERLY REVENUE S$’000 35,000 32,737 31,441 30,699 30,000 29,002 27,004 10,134 25,000 10,210 11,403 9,730 9,742 20,000 3,821 3,589 3,638 4,655 15,000 3,426 10,000 18,782 15,634 16,900 15,383 13,836 5,000 0 1Q2019 2Q2019 3Q2019 4Q2019 1Q2020 Specialty Pharma Principals Propriet

  11. Slide 11: Segment Revenue and Improving Margins

    5/14/2020 1.2 SEGMENT REVENUE Business Segments Geography Malaysia 7% Medical Specialty Others hypermart & pharma 9% digital; 36% principals; Singapore 49% 1Q2020 52% Proprietary Vietnam brands; 15% 32% Malaysia 8% Medical Others hypermart & Specialty 7% digital; 36% pharma principals; 51% 1Q2019 Si

  12. Slide 12: Strong Financial Position & Cash Flow; Maintaining Dividend Policy

    5/14/2020 3 STRONG FINANCIAL POSITION & CASH FLOW S$’000 31 Mar 2020 31 Dec 2019 Total assets 84,031 80,131 Cash & cash equivalents 27,799 26,165 Total liabilities 37,894 36,055 Financial liabilities 720 300 Total equity 46,137 44,076 NAV per share (cents) 15.36 14.67 S$’000 1Q2020 1Q2019 Cashflow f

  13. Slide 13: Management Ownership

    5/14/2020 5 MANAGEMENT OWNERSHIP Public Float3, 19.8% Executive Inomed Director², Holding¹, 14.6% 65.3% ¹ Owned by Mr. Lim See Wah, CEO and Dr. Tan Kia King, Non- Executive Director ² Mr. Tan Chwee Choon, Executive Director 3 As at 11 Mar 2020 Hyphens Pharma International Limited (SGX: 1J5) 16 Tai S

Hyphens Pharma International — Q1 2020 Earnings Presentation on 6ix